Clinical Trial Update: Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating Palbociclib combined with nab-paclitaxel in metastatic pancreatic ductal adenocarcinoma has completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Palbociclib (palbociclib)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: COMPLETED | Results posted: 2021-04-06